Literature DB >> 10416484

[Roaming through the methodology. XIV. The premature ending of a randomized trial].

J P Vandenbroucke1.   

Abstract

A randomized controlled trial that is stopped prematurely because of a striking benefit or a strong untoward effect is most probably suffering from a 'random high'. At premature stopping the conclusions will often either be too optimistic or too pessimistic. In the early phases of an investigation the intermediate results show wider fluctuations around the hypothetical 'truth' than in the later phases. Subjective arguments involved in the stopping of a trial may be eliminated by a so-called triple blind design: the data monitoring and safety committee receives the intermediate results but is not told which data are from the experimental group and which ones from the placebo group.

Mesh:

Year:  1999        PMID: 10416484

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

Review 1.  When drug companies select what they want to publish patients are denied relevant therapeutic information.

Authors:  Graziella Filippini; Lorenzo Moja; Alessandro Liberati; Gian Franco Gensini; Roberto Gusinu; Andrea A Conti
Journal:  Intern Emerg Med       Date:  2008-09       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.